This article is more than 5 years old. Information may no longer be current.
Greater mortality in patients after hip fracture surgery than elective THR
In this study, patients who underwent hip fracture surgery had a higher chance of in-hospital mortality after adjustment for age, sex and comorbidities than patients who underwent elective total hip replacement.
Researchers included 690,995 patients from the French National Hospital Discharge Database, 371,191 of whom underwent elective total hip replacement (THR) and 319,804 of who underwent hip fracture surgery at 864 French hospitals between January 2010 and December 2013. They collected data on patient age and sex, primary diagnosis, procedures performed during hospital stay, length of stay (LOS), in-house complications and mortality.
Researchers also used the International Statistical Classification of Diseases and related Health Problems, 10th Revision codes to \determine patients’ comorbidities and postoperative complications. Then, a multivariable logistic model was used to create a matched population of patients who underwent either elective THIR or hip fracture surgery.
The matched population analysis showed patients who underwent elective THR were younger and had less postoperative comorbidities. Patients who underwent hip fracture surgery had a longer mean LOS. Patients were discharged to their home less frequently following hip fracture surgery and were more likely to be readmitted to the hospital after 72 hours vs. patients who underwent elective THR. In-hospital mortality during a readmission was greater in patients who underwent hip fracture surgery vs. patients who underwent elective THR, the findings showed.
“Patients undergoing surgery for a hip fracture were older and had more comorbidities than patients who underwent elective THR, and these differences accounted for some of the difference in outcomes between these groups,” the authors wrote. “Further studies are needed to define the causes for these differences.” ‒ by Monica Jaramillo
Disclosure: Le Manach reports no relevant financial disclosures.